Skip to main content
Figure 4 | BMC Cancer

Figure 4

From: The combination of gefitinib and RAD001 inhibits growth of HER2 overexpressing breast cancer cells and tumors irrespective of trastuzumab sensitivity

Figure 4

Efficacy of gefitinib, RAD001 and the combination in JIMT-1 and MCF7-HER2 tumors. S.c. tumors were established in Rag2M mice and animals were treated for 28 days (JIMT-1) or 25 days (MCF7-HER2) with the indicated drugs. Growth curves of (A) JIMT-1 and (B) MCF7-HER2 tumors (n = 6 mice/treatment group) plotted based on tumor volume. Numbers in figure legends indicate drug doses in mg/kg of body mass. Asterisks represent a significant (p < 0.05) difference between the average tumor volume on the last day of treatment between indicated groups.

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us